Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LIK066 placebo-controlled phase 2 study in obese patients with NASH
NL-OMON44568Phase 2Active, not recruiting
- Sponsor
- Novartis
- Start
- Dec 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of licogliflozin in metabolic dysfunction-associated steatohepatitis (MASH) (3 arms), sponsored by Novartis. Primary endpoint: Change in circulating alanine aminotransferase levels. Started Dec 2017; status: active, not recruiting.
02
Drugs
licogliflozin
03
Conditions
metabolic dysfunction-associated steatohepatitis (MASH)
Beyond the preview
Go deeper on NL-OMON44568.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON44568.